ADMA
ADMA Biologics, Inc.NASDAQHealthcare$9.19+0.88%ClosedMarket Cap: $2.19B
As of 2026-04-06
Valuation
P/E (TTM)
14.90
PEG
—
P/B
4.63
P/S
4.33
EV/EBITDA
11.13
DCF Value
$-123.45
FCF Yield
1.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
57.4%
Operating Margin
37.5%
Net Margin
28.8%
ROE
35.0%
ROA
23.5%
ROIC
27.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $139.2M | 63.8% | $62.8M | $49.4M | $0.20 | — |
| FY 2025 | $510.2M | 57.4% | $191.4M | $146.9M | $0.60 | — |
| Q3 2025 | $134.2M | 56.3% | $51.0M | $36.4M | $0.15 | — |
| Q2 2025 | $122.0M | 55.1% | $42.8M | $34.2M | $0.14 | — |
| Q1 2025 | $114.8M | 53.2% | $34.9M | $26.9M | $0.11 | — |
| Q4 2024 | $117.5M | 53.9% | $38.3M | $111.9M | $0.46 | — |
| FY 2024 | $426.5M | 51.5% | $139.0M | $197.7M | $0.81 | — |
| Q3 2024 | $119.8M | 49.8% | $39.6M | $35.9M | $0.15 | — |
| Q2 2024 | $107.2M | 53.6% | $39.2M | $32.1M | $0.13 | — |
| Q1 2024 | $81.9M | 47.8% | $21.8M | $17.8M | $0.08 | — |
| Q4 2023 | $73.9M | 42.1% | $14.2M | $-17.6M | $-0.08 | — |
| FY 2023 | $258.2M | 34.4% | $21.6M | $-28.2M | $-0.13 | — |